4.7 Article

Associations of miR-181a with Health-Related Quality of Life, Cognitive Functioning, and Clinical Data of Patients with Different Grade Glioma Tumors

Related references

Note: Only part of the references are listed.
Review Biochemistry & Molecular Biology

Glioma targeted therapy: insight into future of molecular approaches

Keyang Yang et al.

Summary: Gliomas are common brain tumors originating from glial cells. Treatment and prognosis differ significantly depending on the type of glioma. Traditional targeted therapy approaches have faced challenges, while new methods such as immunotherapy and the tumor microenvironment are gaining interest. More clinical trials are needed to evaluate the feasibility of personalized targeted therapy.

MOLECULAR CANCER (2022)

Article Biotechnology & Applied Microbiology

MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway

Zhen Zhai et al.

Summary: miR-181a-5p facilitates tumor progression by activating the PTEN/AKT signaling pathway through its regulation of NDRG2.

BIOENGINEERED (2022)

Article Oncology

Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas

Jianing Wu et al.

Summary: This study found that circulating miR-181a/b, miR-410, and miR-155 could be useful diagnostic and prognostic biomarkers for high-grade gliomas.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

The Metalloprotease-Disintegrin ADAM8 Alters the Tumor Suppressor miR-181a-5p Expression Profile in Glioblastoma Thereby Contributing to Its Aggressiveness

Agnes Schafer et al.

Summary: This study found that ADAM8 downregulates the expression of miR-181a-5p by activating the STAT3 and MAPK signaling pathways, thereby increasing the proliferation of GBM cells and enhancing the expression of MMP9. MiR-181a-5p can downregulate the expression of MMP9 by targeting the MAPK signaling pathway, thereby inhibiting the progression of GBM tumors.

FRONTIERS IN ONCOLOGY (2022)

Review Oncology

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

Jue Hou et al.

Summary: Molecular targeted therapy has significantly improved cancer treatment by providing better therapeutic responses and reducing systemic toxicity. However, therapeutic resistance remains a major challenge, hindering the continuous clinical benefits for cancer patients. The recent development of advanced technologies, such as CRISPR-Cas9 screening and patient-derived models, has provided powerful tools to understand the underlying mechanisms of resistance in targeted cancer therapies. This review explores therapeutic targets and the high-throughput CRISPR-Cas9 screening technology, which can uncover potential mechanisms of unresponsiveness and guide the development of next-generation anti-cancer drugs.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines

Lucy Wanjiku Macharia et al.

Summary: This study reveals that miRNAs are dysregulated, stemness factors are induced, and alteration of survival genes occurs in GBM cells when exposed to a hypoxic tumor microenvironment, potentially contributing to GBM aggressiveness.

BMC CANCER (2021)

Review Oncology

Current status and recent advances in reirradiation of glioblastoma

Giuseppe Minniti et al.

Summary: Reirradiation has shown survival benefits for patients with recurrent GBM, but questions remain about the efficacy and toxicity of a second course of radiation. Current clinical discussions on reirradiation of GBM focus on appropriate patient selection, radiation technique, optimal dose fractionation, brain tolerance to reirradiation, and the risk of radiation necrosis.

RADIATION ONCOLOGY (2021)

Article Engineering, Chemical

Impact of MiRNA-181a2 on the Clinical Course of IDH1 Wild Type Glioblastoma

Christoph Sippl et al.

Summary: The study identified a correlation between miRNA-181a2 expression and IDH1 mutation in glioblastoma patients, with potential prognostic value for those with IDH1 wild type characteristics.

PROCESSES (2021)

Review Biochemistry & Molecular Biology

Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity

Gabor Hutoczki et al.

Summary: Despite improvement in treatment outcomes of glioblastoma over the past decades, it remains incurable. Advances in molecular biology and genetics have provided new insights, yet current anti-proliferative therapies are not very effective. Liquid biopsy is a promising new diagnostic tool that can monitor dynamic genetic changes in tumors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Article Chemistry, Multidisciplinary

Expression of miR-181a in Circulating Tumor Cells of Ovarian Cancer and Its Clinical Application

Li Zuo et al.

Summary: Detection of miR-181a in circulating tumor cells (CTCs) of ovarian cancer patients may allow for early diagnosis and prognostic evaluation. MiR-181a could be involved in the development and progression of ovarian cancer as an oncogene. The expression of miR-181a in CTCs captured by EpCAM liposome magnetic beads (Ep-LMBs) correlates with clinical characteristics of ovarian cancer.

ACS OMEGA (2021)

Review Genetics & Heredity

Molecular profiling for precision cancer therapies

Eoghan R. Malone et al.

GENOME MEDICINE (2020)

Review Oncology

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

Sue Han et al.

BRITISH JOURNAL OF CANCER (2020)

Review Biochemistry & Molecular Biology

The Pervasive Role of the miR-181 Family in Development, Neurodegeneration, and Cancer

Alessia Indrieri et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Biotechnology & Applied Microbiology

Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis

Wei-Xiao Xue et al.

BIOMED RESEARCH INTERNATIONAL (2020)

Article Biochemistry & Molecular Biology

Unique Interplay between Molecular miR-181b/d Biomarkers and Health Related Quality of Life Score in the Predictive Glioma Models

Rytis Stakaitis et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Biochemistry & Molecular Biology

miRNA-based biomarkers, therapies, and resistance in Cancer

Boxue He et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)

Review Oncology

The role and mechanisms of action of microRNAs in cancer drug resistance

Wengong Si et al.

CLINICAL EPIGENETICS (2019)

Review Cell Biology

An overview of microRNAs: Biology, functions, therapeutics, and analysis methods

Kioomars Saliminejad et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Article Oncology

Role of the microRNA 181 family in glioma development

Liu Yang et al.

MOLECULAR MEDICINE REPORTS (2018)

Review Medicine, Research & Experimental

Role of miR-181a in the process of apoptosis of multiple malignant tumors: A literature review

Xialu Feng et al.

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE (2018)

Article Biochemistry & Molecular Biology

The Somatic Genomic Landscape of Glioblastoma

Cameron W. Brennan et al.

Article Dentistry, Oral Surgery & Medicine

miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma

Cheng-Chieh Yang et al.

JOURNAL OF ORAL PATHOLOGY & MEDICINE (2011)

Review Biochemistry & Molecular Biology

Biological functions of microRNAs: a review

Yong Huang et al.

JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2011)

Article Health Care Sciences & Services

The PHQ-9 - Validity of a brief depression severity measure

K Kroenke et al.

JOURNAL OF GENERAL INTERNAL MEDICINE (2001)